Prof. Xiaorong Dong 董晓荣
Chief Physician, Professor
Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and individualized treatment of lung cancer, esophageal cancer, and mediastinal tumors using radiotherapy, chemotherapy, molecular targeted therapy, immunotherapy, and international new drug clinical trials.
Dr. Dong graduated from Tongji Medical University in 1999 and has focused on oncology radiotherapy and chemotherapy since. After studying in Germany (2005–2007) and earning a PhD in April 2007, Dr. Dong joined the Huazhong University of Science and Technology postdoctoral station in July 2009. Research focuses on mechanisms of lung cancer brain metastasis and radiation injury prevention.
Professional roles
- Vice Director, Department of Oncology and Teaching Section, Union Hospital
- Director, Thoracic Oncology Department, Cancer Center, Union Hospital
- Council Member, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Immunology Professional Committee, CSCO
Name order: in Chinese the family name comes first (Dong Xiaorong). Papers usually list the name as Xiaorong Dong or Dong X.
Selected publications
175 papers on PubMed matched by name and affiliation; 43 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Diagn Ther, 2026 (senior author): Development of Diagnostic Models and Biomarker Identification for Type 1 Leptomeningeal Metastasis in Lung Adenocarcinoma Using Olink: Exploratory Cohort Study with Internal Temporal Validation. PubMed 42804151
- Lung Cancer, 2026 (first author): Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort. PubMed 41785639
- Radiother Oncol, 2025 (senior author): Analysis of discontinued radiotherapy trials registered on ClinicalTrials.gov between 2014 and 2024. PubMed 41052605
- Cancer Pathog Ther, 2025 (senior author): Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study. PubMed 41179943
- Oncologist, 2025 (senior author): Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study. PubMed 40990807
- Chin Med J (Engl), 2025 (senior author): Role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study. PubMed 39307928
- Cell Death Dis, 2025 (senior author): Roles of the phagocytosis checkpoint in radiotherapy. PubMed 40835598
- Transl Lung Cancer Res, 2025 (senior author): Comparison of the effectiveness of alectinib versus crizotinib followed by alectinib in patients with ALK-positive advanced non-small-cell lung cancer in real-world setting and in the ALEX study. PubMed 40386712
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion